Mineralys Therapeutics, Inc. (MLYS)
$21.00-5.53%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.9B
- Beta
- 0.69
- P/E (TTM)
- -4.95
- Short % float
- 12.03%
- Days to cover
- 5.2
- SI change
- -15.0%
- 1W
- -4.33%
- 1M
- -27.46%
- vs SPY 1W
- -4.19%
- vs SPY 1M
- -29.97%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 8
- GROWTH
- 45
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-34.8%
REV YoY-
ROE-58.0%
EPS YoY-
ROA-52.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-4.95
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B3.23
P/FCF-
EV/EBITDA-5.18
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E17.72
ALTMAN Z-
CURR RATIO34.46
ND/EBITDA-
BETA0.69
Company news
FAQ
- What is LOPJLB’s current signal on MLYS?
- LOPJLB’s latest quantitative signal on Mineralys Therapeutics, Inc. (MLYS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MLYS in?
- Mineralys Therapeutics, Inc. (MLYS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Mineralys Therapeutics, Inc. (MLYS) do?
- Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected…